Register
Login

Trending Topic

15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular disease (CVD) continues to be the primary cause of mortality and morbidity globally with middle-aged women presenting with additional and possibly, overlooked risk factors.1 Despite several awareness programmes, there remain several gaps in the political education and representation needs of this group, which includes those from low socioeconomic status (SES) and culturally diverse backgrounds. These […]

Jean Claude Tardif, AHA 2019 – Results from the COLCOT trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 12th 2019

Jean-Claude Tardif (Director of the Research Centre, Montreal Heart Institute and Professor of Medicine, University of Montreal, Montreal, QC, Canada) reviews the results from the COLchicine Cardiovascular Outcomes Trial (COLCOT), presented at the American Heart Association (AHA) Scientific Sessions 2019.

Speaker’s Disclosures: Dr. Tardif reports grants from Government of Quebec; grants from Amarin, grants and personal fees from Astra Zeneca, grants, personal fees and other from DalCor, grants from Esperion, grants from Ionis, grants and personal fees from Pfizer, grants and personal fees from Sanofi, grants and personal fees from Servier.

touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup